Suprith Badarinath

962 total citations
16 papers, 309 citations indexed

About

Suprith Badarinath is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Suprith Badarinath has authored 16 papers receiving a total of 309 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Cancer Research. Recurrent topics in Suprith Badarinath's work include Cancer Treatment and Pharmacology (11 papers), Colorectal Cancer Treatments and Studies (9 papers) and Gastric Cancer Management and Outcomes (5 papers). Suprith Badarinath is often cited by papers focused on Cancer Treatment and Pharmacology (11 papers), Colorectal Cancer Treatments and Studies (9 papers) and Gastric Cancer Management and Outcomes (5 papers). Suprith Badarinath collaborates with scholars based in United States and Netherlands. Suprith Badarinath's co-authors include Allen Lee Cohn, Mary M. Sugrue, John D. Hainsworth, Axel Grothey, Wei Dong, Mark Kozloff, Patrick J. Flynn, Shaker R. Dakhil, Eric Hedrick and Ralph V. Boccia and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Breast Cancer Research and Treatment.

In The Last Decade

Suprith Badarinath

16 papers receiving 301 citations

Peers

Suprith Badarinath

ONCOL

PRM

HEPAT

SURGE

M. Kozloff United States

Dario Nicolella Italy

M. Frueh Switzerland

C.J.A. Punt Netherlands

C. Bosch Spain

J.-L. Canon Belgium

Javier Rodríguez Spain

J.F. Seitz France

J Lokich United States

Yoko Fukuda Japan

M. Kozloff United States

Suprith Badarinath

273 ×1.0

ONCOL

138 ×1.2

PRM

64 ×1.1

HEPAT

54 ×1.0

26 ×0.5

SURGE

Citations per year, relative to Suprith Badarinath Suprith Badarinath (= 1×) peers M. Kozloff

Countries citing papers authored by Suprith Badarinath

Since Specialization

Citations

This map shows the geographic impact of Suprith Badarinath's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suprith Badarinath with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suprith Badarinath more than expected).

Fields of papers citing papers by Suprith Badarinath

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suprith Badarinath. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suprith Badarinath. The network helps show where Suprith Badarinath may publish in the future.

Co-authorship network of co-authors of Suprith Badarinath

This figure shows the co-authorship network connecting the top 25 collaborators of Suprith Badarinath. A scholar is included among the top collaborators of Suprith Badarinath based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suprith Badarinath. Suprith Badarinath is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Berenson, James R., Robert Manges, Suprith Badarinath, et al.. (2017). A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma. American Journal of Hematology. 92(5). 460–466. 13 indexed citations

Schwartzberg, Lee S., Suprith Badarinath, Mark Keaton, & Barrett H. Childs. (2014). Phase II Multicenter Study of Docetaxel and Bevacizumab With or Without Trastuzumab as First-Line Treatment for Patients With Metastatic Breast Cancer. Clinical Breast Cancer. 14(3). 161–168. 9 indexed citations

Chew, Helen K., Lee S. Schwartzberg, Suprith Badarinath, et al.. (2014). Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer. SpringerPlus. 3(1). 108–108. 2 indexed citations

Yardley, Denise A., Lowell L. Hart, David Waterhouse, et al.. (2013). Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer. Breast Cancer Research and Treatment. 142(3). 655–665. 6 indexed citations

Thomas, Sachdev, Suprith Badarinath, Richard H. Greenberg, et al.. (2012). MAVERICC: A randomized phase II study of mFOLFOX6-bevacizumab (BV) versus FOLFIRI-BV with prospective biomarker stratification in previously untreated metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 30(15_suppl). TPS3635–TPS3635. 5 indexed citations

Saltz, Leonard B., Suprith Badarinath, Shaker R. Dakhil, et al.. (2011). Phase III Trial of Cetuximab, Bevacizumab, and 5-Fluorouracil/Leucovorin vs. FOLFOX-Bevacizumab in Colorectal Cancer. Clinical Colorectal Cancer. 11(2). 101–111. 58 indexed citations

Lenz, H. J., Mansoor N. Saleh, Suprith Badarinath, et al.. (2011). A fixed-sequence, open-label study to determine the activity of SCH 717454 (robatumumab) as assessed by positron emission tomography in patients with relapsed or recurrent colorectal cancer.. Journal of Clinical Oncology. 29(15_suppl). 3584–3584. 1 indexed citations

Boccia, Ralph V., et al.. (2010). A Phase II Trial of FOLFOX6 and Cetuximab in the First-line Treatment of Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 9(2). 102–107. 20 indexed citations

Yardley, DA, et al.. (2009). Preliminary safety results: addition of bevacizumab to 3 docetaxel regimens as adjuvant therapy for early stage breast cancer.. Cancer Research. 69(2_Supplement). 4107–4107. 8 indexed citations

10.

Badarinath, Suprith, et al.. (2008). A multicenter study of 3 docetaxel regimens with bevacizumab as adjuvant therapy for breast cancer (BC): Preliminary results. Journal of Clinical Oncology. 26(15_suppl). 575–575. 4 indexed citations

11.

Sugrue, Mary M., M. Kozloff, John D. Hainsworth, et al.. (2007). 3048 POSTER Safety and effectiveness of bevacizumab (BV) plus chemotherapy (CT) in elderly patients with mCRC: results from the BRiTE registry. European Journal of Cancer Supplements. 5(4). 250–250. 7 indexed citations

12.

Kozloff, M., John D. Hainsworth, Suprith Badarinath, et al.. (2007). 3049 POSTER Management of hypertension (HTN) in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab (BV) plus chemotherapy (CT). European Journal of Cancer Supplements. 5(4). 250–251. 12 indexed citations

13.

Dakhil, Shaker R., et al.. (2006). Cetuximab + FOLFOX6 as first line therapy for metastatic colorectal cancer (An International Oncology Network study, I-03–002). Journal of Clinical Oncology. 24(18_suppl). 3557–3557. 15 indexed citations

14.

Sugrue, Mary M., Mark Kozloff, John D. Hainsworth, et al.. (2006). Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. Journal of Clinical Oncology. 24(18_suppl). 3535–3535. 60 indexed citations

15.

Hedrick, Eric, Mark Kozloff, John D. Hainsworth, et al.. (2006). Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE). Journal of Clinical Oncology. 24(18_suppl). 3536–3536. 77 indexed citations

16.

Krishnan, Kumar, et al.. (1986). Vascular complications of hepatic amoebiasis--a retrospective study.. PubMed. 29(3). 293–6. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact